Have you ever stared at a supplement bottle and thought, “Is this stuff safe?” Spoiler: In the UK, the answer is almost always “yes”—and it’s all thanks to some pretty strict rules. However, between Brexit shake-ups and the buzz around trendy ingredients like NMN, it’s easy for consumers to feel confused. Let’s break down everything you need to know about UK supplement regulations, from what makes a supplement “legal” to whether that NMN you’ve heard about is okay to buy.

The article discusses the uncertain future of NMN in the US due to potential FDA restrictions. The FDA's move to ban NMN as a supplement is based on regulatory issues, not safety concerns. A court stay has paused legal proceedings while the FDA reviews a petition. Possible outcomes include a reversal of the ban, temporary availability, or a formal ban.

Do you manufacture or sell food supplements? Or are you simply looking to discover how nutritional supplements, such as novel food ingredients, are regulated in the EU? We understand it can be tricky to navigate the complex EU Novel Food Regulation, especially with all the legal terms and procedures involved. That’s why, having successfully guided our own product through this process, we’re here to share what we’ve learned. At EffePharm, our UTHEVER® NMN is leading the way in EU Novel Food compliance—proving that with the right expertise, bringing innovative supplements like NMN to the EU market is absolutely achievable within 2025.

UTHEVER® NMN is now the first NMN product to have finished the EU NOVEL FOOD public consultation phase (February 2025), bringing it the first to reach the EFSA’s risk assessment. Approval is currently pending, marking us as the fastest in the EU compliance race among all applicants.

As the industry awaits a final decision on NMN’s regulatory status and the FDA’s response to the ongoing petition, one thing remains clear: NMN’s safety and effectiveness have been consistently demonstrated through years of use in the dietary supplement market.

–EffePharm Announces Self-GRAS for Its New NAD+ Booster, UthPeak™ NMNH– SHANGHAI, China, Sept. 05, 2024 – EffePharm has announced that its proprietary UthPeak™ NMNH (reduced NMN) has achieved self-affirmed GRAS (generally recognized as safe) status following a recent review by an independent panel of qualified scientific and toxicology experts. In accordance with Food and Drug Administration (FDA) requirements, the panel agreed that the data demonstrate UthPeak™ NMNH can be sold, used, and consumed in the U.S. food supply. UthPeak™, marketed as "The Next-Gen Super NAD+ Enhancer," is a patent-pending crystalline NMNH that has demonstrated a remarkable 10X surge in NAD+ levels. UthPeak™ is believed to be the first NMNH brand to receive self-affirmed GRAS as a new generation NAD+ precursor. "The self-affirmed GRAS status is a testament to the safety and innovation of UthPeak™ NMNH and marks an essential step on our path toward commercialization," said Dr. Jianjun YU, EffePharm’s R&D Director. "At EffePharm, our business philosophy is rooted in delivering unique market value backed by scientific evidence. From our patent-protected crystalline form to extensive clinical studies, we believe UthPeak™ NMNH will provide distinct competitive advantages, enriching our clients' product offerings and enhancing their brand value. UthPeak™ Preclinical and Clinical…